Repeated SMA Treatment With Nusinersen Does Not Result in Consistent Increase in Immune Responses
December 23rd 2022The findings, say the researchers, confirm that repeated intrathecal injections of the gene-targeting therapy are safe, adding to the limited data on the long-term effect and safety of the treatment approach in neurological diseases.
Read More
Top 5 Most-Read Rare Disease Articles of 2022
December 23rd 2022The most-read rare disease articles of the year included the topics of new pediatric central nervous system tumor guidelines, graft versus host disease, the contribution of gene variants to pediatric neuropsychiatric conditions, and hope for patients with blast-phase chronic myeloid leukemia.
Read More
Top 5 Most-Read Skin Cancer Articles of 2022
December 23rd 2022BRAF mutations were addressed in depth this year, having been mentioned in 3 of this year’s top 5 articles. Also discussed were a first-in-its-class combination treatment approval and potential indicators of increased skin cancer risk.
Read More
Raising the Overall Awareness for Infantile Spasms, Early Recognition of Pre-Epilepsy Diagnosis
December 22nd 2022Martina Bebin, MD, MPA, professor of neurology, University of Alabama at Birmingham Epilepsy Center, discussed Infantile Spasms Awareness Week, the strides made within the field, and the emphasis on early and accurate diagnosis.
Read More
Kidney Tubular Secretion Associated With Faster eGFR Decline
December 22nd 2022Lower estimated tubular secretion was found to be associated with a faster decline of estimated glomerular filtration rate (eGFR) but wasn’t associated with progression of chronic kidney disease or cardiovascular disease.
Read More
Top 5 Most-Read Immuno-Oncology Articles of 2022
December 22nd 2022In 2022, the most-read news about immuno-oncology included an FDA approval for liver cancer, research findings on other potential therapies for liver cancer, a Q&A with a COTA Healthcare executive about how real-world evidence has changed, new possibilities for patients with solid tumors, and more.
Read More
Adjuvant Baricitinib, Topical Corticosteroids Show Long-term Efficacy in Moderate-to-Severe AD
December 22nd 2022Adult patients with moderate-to-severe atopic dermatitis (AD) in the phase 3 BREEZE-AD7 study showed sustained improvement of AD signs and symptoms after 68 weeks with combination treatment of bariticitinib and topical corticosteroids.
Read More
Top 5 Most-Read COVID-19 News of 2022
December 22nd 20222022's most-read news about the pandemic included the impact of COVID-19 on patients with asthma, the Biden administration's plans to advance vaccination and other initiatives, information about when SARS-CoV-2 is at its most infectious, and more.
Read More
Dr Davey Daniel Talks Approval of Cemiplimab With Chemotherapy for First-line NSCLC
December 21st 2022Cemiplimab with chemotherapy appears to offer value comparable to other options and may be "an important tool to use" in first-line treatment of non-small cell lung cancer (NSCLC), said Davey Daniel, MD, chief medical officer for OneOncology, lung cancer specialist.
Watch
The new federal spending bill includes changes to Medicaid enrollment, postpartum coverage, and other health programs; new research shows widened disparities among US adults with diabetes using insulin; in 2022, the Drug Enforcement Administration confiscated more than 379 million fentanyl doses.
Read More
Dr Jessica Allegretti Explains Rebyota’s Mechanism of Action for the Prevention of Recurrent CDI
December 21st 2022Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, explained the mechanism of action for Rebyota, the first fecal transplant therapy approved by the FDA for the prevention of recurrent Clostridioides difficile infection (CDI) in individuals 18 years and older, following antibiotic treatment for recurrent CDI.
Watch